On August 22, researchers at the National Institutes of Health released a scientific paper detailing the use of advanced genetic technology to trace a deadly infection, untreatable by nearly every antibiotic, that spread through the NIH’s Clinical Center last year. The superbug eventually infected 17 patients. Eleven died, six from bloodstream superbug infections. Nicole Mahoney, Senior Officer of the Antibiotics and Innovation Project at the Pew Health Group, says this case illustrates the need for the development of new antibiotics to treat life-threatening illnesses.
- 'Superbug' Stalked NIH Hospital Last Year, Killing Six (Washington Post)
- NIH Superbug Outbreak Highlights Lack of New Antibiotics (Washington Post)
- Tracking a Superbug at NIH (Washington Post editorial)
- Use of Last-Resort Antibiotics Rises in VA Hospitals, National Study Finds
- Date added:
- Aug 23, 2012
Surveys of the animal production industry by the U.S. Department of Agriculture demonstrate that many farms and ranches administer antibiotics to healthy animals at low doses to offset overcrowding and poor sanitation and to accelerate livestock growth—practices that the medical and public health communities document as a significant factor in human antibiotic resistance. In 2013, FDA took steps to address these concerns.
In the State of the Union address, President Barack Obama recognized the need to “stay ahead of drug-resistant bacteria” and that developing therapies to fight these threats is an opportunity for American innovation and discovery. The threat of drug-resistant bacteria is real, and the need for antibiotic development clear.More info
A bipartisan group of representatives introduced in the U.S. House of Representatives a bill that would create an accelerated approval pathway for antibiotics and antifungals for use in limited populations and would update the criteria that HHS uses to determine breakpoints for drugs.More info
Letter from Pew Thanking Representatives Gingrey and Green for Leadership on New Antibiotics LegislationRepresentatives Phil Gingrey (R-GA) and Gene Green (D-TX) introduced legislation intended to bring antibiotics to patients with few other treatment options. In a letter, Pew called the bill, named the Antibiotic Development to Advance Patient Treatment (ADAPT) Act, “a welcome step towards establishing a new regulatory pathway to bring desperately-needed antibiotics to the patients who need them the most.” More info
Chris Linaman, executive chef at Overlake Medical Center in Bellevue, WA, is dedicated to creating a more sustainable food system by supporting growers and producers who raise food without the routine use of antibiotics that endanger the public’s health. Working in partnership with Health Care Without Harm and Overlake’s administration, Chris has created a comprehensive sustainable food purchasing policy for Overlake Hospital that has resulted in many impressive achievements in just a short time.More info
Two former FDA commissioners – David Kessler (1990-1997) and Donald Kennedy (1977-1979) – wrote to OMB Director Sylvia Matthews Burwell urging her to take action on antibiotics in agricultural feed.More info
SuperChefs Against Superbugs, an initiative of the Pew Campaign on Human Health and Industrial Farming, is a movement of chefs nationwide who have expressed their support of ending the misuse and overuse of antibiotics in food animal production. As a result, the SuperChefs are urging the Food and Drug Administration to strengthen its antibiotic policies.More info
On July 9, 2012, the Generating Antibiotic Incentives Now, or GAIN, provisions were signed into law by President Barack Obama as part of the Food and Drug Administration Safety and Innovation Act. This bipartisan legislation extends by five years the exclusivity period during which certain antibiotics—those that treat serious or life-threatening infections—can be sold without generic competition. This additional period of exclusivity increases the potential for profits from new antibiotics by giving innovative companies more time to recoup their investment costs.More info
In comments to the U.S. Food and Drug Administration, Pew asked the agency to improve the way it reports annual sales of antibiotics for use in food animal production. Chief among its recommendations, Pew urged the FDA to amend the definition of “therapeutic” antibiotic use to more clearly exclude inappropriate uses for so-called “disease prevention” purposes that, in practice, are similar or identical to growth promotion.More info